参考文献/References:
[1]Michael DS.Digestion and absorption of dietary triglycerides.In:Leung Po Sing,editor.The gastrointestinal system:gastrointestinal,nutritional and hepatobiliary physiology[M].New York:E-Publishing Inc,2014:160-178.
[2]Huang H,Mc Intosh AL,Martin GG,et al.Structural and functional interaction of fatty acids with human liver fatty acid binding protein(L-FABP)T94A variant[J].FEBS J,2014,281(9):2266-2283.
[3]Atshaves BP,Martin GG,Hostetler HA,et al.Liver fatty acid binding protein and obesity[J].J Nutr Biochem,2010,21(6):1015-1032.
[4]Martin GG,Atshaves BP,McIntosh AL,et al.Liver fatty acid-binding protein gene-ablated female mice exhibit increased age-dependent obesity[J].J Nutr,2008,138(10):1859-1865.
[5]Schachtrup C,Emmler T,Bleck B,et al.Functional analysis of peroxisome proliferator responsive element motifs in genes of fatty acid binding proteins[J].Biochem J,2004,382(Pt1):239-245.
[6]Chen XY,Li R,Geng ZY.Cold stress initiates the Nrf2/UGT1A1/L-FABP signaling pathway in chickens[J].Poult Sci,2015,94(11):2597-2603.
[7]Hyunwoo Kim,Gaae Gil,Siyoung Lee,et al.Cytokine-like Activity of Liver Type Fatty Acid Binding Protein(L-FABP)Inducing Inflammatory Cytokine Interleukin-6[J].Immune Netw,2016,16(5):296-304.
[8]Huang H,Mcintosh AL,Martin GG,et al.Inhibitors of Fatty Acid Synthesis Induce PPARα-Regulated Fatty Acid β-Oxidative Genes:Synergistic Roles of L-FABP and Glucose[J].PPAR Research,2013,2013(2013):865604.
[9]Ichikawa D,Kamijo-Ikemori A,Sugaya T,et al.Renal liver-type fatty acid binding protein attenuates angiotensin Ⅱ-induced renal injury[J].Hypertension,2012,60(4):973-980.
[10]Yang J,Choi HM,Seo MY,et al.Urine liver-type fatty acid-binding protein predicts graft outcome up to 2 years after kidney transplantation[J].Transplant Proc,2014,46(2):376-380.
[11]Parr SK,Clark AJ,Bian A,et al.Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury[J].Kidney Int,2015,87(3):640-648.
[12]Belcher JM,Garcia-Tsao G,Sanyal AJ,et al.Urinary biomarkers and progression of AKI in patients with cirrhosis[J].Clin J Am Soc Nephrol,2014,9(11):1857-1867.
[13]Viswanathan V,Sivakumar S,Sekar V,et al.Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy[J].Indian J Nephrol,2015,25(5):269-273.
[14]黄志勇,王利,汪慧,等.糖尿病肾病患者尿L-FABP的检测及其临床意义[J].武汉大学学报,2015,36(2):266-269.
[15]Araki SI,Haneda M,Koya D,et al.Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy[J].Diabetes Care,2013,36(5):1248-1253.
[16]Abd El Dayem S,El Bohy Ael M,El Shehaby A.Follow up of value of the intrarenal resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients[J].J Pediatr Endocrinol Metab,2016,29(3):273-279.
[17]Fu WJ,Wang DJ,Deng RT,et al.Urinary liver-type fatty acid-binding protein Change in gestational diabetes mellitus[J].Diabetes Res Clin Pract,2015,109(3):e36-e38.
[18]Suh JS,Kim SH,Cho KS,et al.Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes[J].Pediatr Nephrol,2016,31(4):623-631.
[19]Chou KM,Lee CC,Chen CH,et al.Clinical value of NGAL,L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients[J].PLoS One,2013,8(1):e54863.
[20]Hiroyuki Ito,Hitomi Yamashita,Mina Nakashima,et al.Current metabolic status affects urinary liver-type fatty-acid binding protein in normoalbuminuric patients with type 2 diabetes[J].J Clin Med Res,2017,9(4):366-373.
[21]Maeda Y,Suzuki A,Ishii J,et al.Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2[J].Heart Vessels,2014,30(3):362-368.
[22]Atsuko Kamijo-Ikemori A,Sugaya T,Sekizuka A,et al.Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice[J].Nephrol Dial Transplant,2009,24(3):788-800.
[23]Panduru NM,Forsblom C,Saraheimo M.Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 Diabetes[J].Diabetologia,2017,60(9):1782-1790.
[24]Nakamura T,Fujiwara N,Sato E,et al.Renoprotective Effects of Various Angiotensin Ⅱ Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy[J].Kidney Blood Press Res,2010,33(3):213-220.
[25]Abe M,Oikawa O,Okada K,et al.Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin Ⅱ type 1 receptor blocker olmesartan[J].J Renin Angiotensin Aldosterone Syst,2015,16(1):159-164.
[26]Abe M,Maruyama N,Okada K,et al.Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria[J].Hypertens Res,2011,34(8):935-941.
[27]Kitada M,Tsuda SI,Konishi K,et al.Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner[J].BMJ Open Diabetes Res Care,2017,5(1):e000391.
[28]Makino H,Matsuo M,Hishida A,et al.Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes:a pilot study[J].Diabetol Int,2018,10(2):148-152.
[29]Wang J,Guo HM.Astragaloside IV ameliorates high glucose-induced HK-2 cell apoptosis and oxidative stress by regulating the Nrf2/ARE signaling pathway[J].Exp Ther Med,2019,17(6):4409-4416.
[30]Yang X,Zhang B,Lu X,et al.Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease:post-hoc findings from a multi-center,randomized,double-blind,placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease[J].BMC Complementary and Alternative Medicine,2016(16):246.
相似文献/References:
[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal
Cancer[J].Journal of Medical Information,2018,31(18):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]耿金萍.综合护理对甲状腺良性肿瘤并糖尿病患者手术效果的影响分析[J].医学信息,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
GENG Jin-ping.Analysis of the Effect of Comprehensive Nursing on the Surgical Effect of Thyroid Benign
Tumor and Diabetic Patients[J].Journal of Medical Information,2018,31(18):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
[3]李雯婷,谈世华,余江明,等.踝肱指数检测在住院糖尿病患者中的重复性研究[J].医学信息,2018,31(03):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
LI Wen-ting,TAN Shi-hua,YU Jiang-ming,et al.Study on Reproducibility of Ankle-brachial Index in Inpatients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
[4]刘 静.冠状动脉粥样硬化性心脏病合并糖尿病的血脂检验结果分析[J].医学信息,2018,31(04):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
LIU Jing.Analysis of Blood Lipid Test Results in Coronary Atherosclerotic Heart Disease Complicated with Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
[5]谢勇丽,苏晓清,张雅薇.糖尿病痛性周围神经病变患者情绪调查分析[J].医学信息,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
XIE Yong-li,SU Xiao-qing,ZHANG Ya-wei.Investigation and Analysis of Mood in Patients with Diabetic Peripheral Neuropathy[J].Journal of Medical Information,2018,31(18):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
[6]张雅薇,朱明慧.首发为动眼神经麻痹的糖尿病合并动眼神经麻痹误诊为痛性眼肌麻痹1例分析[J].医学信息,2018,31(05):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
ZHANG Ya-wei,ZHU Ming-hui.An Analysis of a Case of Diabetes Mellitus with Oculomotor Nerve Palsy Misdiagnosed as Painful Ophthalmoplegia[J].Journal of Medical Information,2018,31(18):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
[7]张宇宁.黄酮类化合物治疗糖尿病及其并发症的研究[J].医学信息,2018,31(05):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
ZHANG Yu-ning.Study on Flavonoids in the Treatment of Diabetes Mellitus and its Complications[J].Journal of Medical Information,2018,31(18):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
[8]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的
临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2018,31(18):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[9]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[10]刘爱君.糖化血红蛋白测定在糖尿病诊断中的应用价值分析[J].医学信息,2018,31(08):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]
LIU Ai-jun.Analysis of the Value of Determination of Glycosylated Hemoglobin in the Diagnosis of Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]
[11]王可欣,马心迪,刘 剑,等.肝型脂肪酸结合蛋白与相关疾病的研究[J].医学信息,2020,33(10):23.[doi:10.3969/j.issn.1006-1959.2020.10.007]
WANG Ke-xin,MA Xin-di,LIU Jian,et al.Study on Liver-type Fatty Acid Binding Proteins and Related Diseases[J].Journal of Medical Information,2020,33(18):23.[doi:10.3969/j.issn.1006-1959.2020.10.007]